These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 22424722)

  • 1. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.
    Kuhn L; Coovadia A; Strehlau R; Martens L; Hu CC; Meyers T; Sherman G; Hunt G; Persaud D; Morris L; Tsai WY; Abrams EJ
    Lancet Infect Dis; 2012 Jul; 12(7):521-30. PubMed ID: 22424722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
    Coovadia A; Abrams EJ; Stehlau R; Meyers T; Martens L; Sherman G; Hunt G; Hu CC; Tsai WY; Morris L; Kuhn L
    JAMA; 2010 Sep; 304(10):1082-90. PubMed ID: 20823434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
    Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
    Shiau S; Kuhn L; Strehlau R; Martens L; McIlleron H; Meredith S; Wiesner L; Coovadia A; Abrams EJ; Arpadi SM
    BMC Pediatr; 2014 Feb; 14():39. PubMed ID: 24521425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.
    Coovadia A; Abrams EJ; Strehlau R; Shiau S; Pinillos F; Martens L; Patel F; Hunt G; Tsai WY; Kuhn L
    JAMA; 2015 Nov; 314(17):1808-17. PubMed ID: 26529159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.
    Alvarez-Uria G; Pakam R; Naik PK; Midde M
    PLoS One; 2014; 9(9):e108063. PubMed ID: 25232730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial.
    Venter WDF; Moorhouse M; Sokhela S; Serenata C; Akpomiemie G; Qavi A; Mashabane N; Arulappan N; Sim JW; Sinxadi PZ; Wiesner L; Maharaj E; Wallis C; Boyles T; Ripin D; Stacey S; Chitauri G; Hill A
    Lancet HIV; 2019 Jul; 6(7):e428-e437. PubMed ID: 31202690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.
    Lockman S; Hughes M; Sawe F; Zheng Y; McIntyre J; Chipato T; Asmelash A; Rassool M; Kimaiyo S; Shaffer D; Hosseinipour M; Mohapi L; Ssali F; Chibowa M; Amod F; Halvas E; Hogg E; Alston-Smith B; Smith L; Schooley R; Mellors J; Currier J;
    PLoS Med; 2012; 9(6):e1001236. PubMed ID: 22719231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
    Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
    Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.
    Murnane PM; Strehlau R; Shiau S; Patel F; Mbete N; Hunt G; Abrams EJ; Coovadia A; Kuhn L
    Clin Infect Dis; 2017 Aug; 65(3):477-485. PubMed ID: 28419200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
    Arribas JR; Girard PM; Landman R; Pich J; Mallolas J; Martínez-Rebollar M; Zamora FX; Estrada V; Crespo M; Podzamczer D; Portilla J; Dronda F; Iribarren JA; Domingo P; Pulido F; Montero M; Knobel H; Cabié A; Weiss L; Gatell JM;
    Lancet Infect Dis; 2015 Jul; 15(7):785-92. PubMed ID: 26062880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.
    Arribas JR; Pialoux G; Gathe J; Di Perri G; Reynes J; Tebas P; Nguyen T; Ebrahimi R; White K; Piontkowsky D
    Lancet Infect Dis; 2014 Jul; 14(7):581-9. PubMed ID: 24908551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
    Molina JM; Lamarca A; Andrade-Villanueva J; Clotet B; Clumeck N; Liu YP; Zhong L; Margot N; Cheng AK; Chuck SL;
    Lancet Infect Dis; 2012 Jan; 12(1):27-35. PubMed ID: 22015077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
    Paton NI; Kityo C; Thompson J; Nankya I; Bagenda L; Hoppe A; Hakim J; Kambugu A; van Oosterhout JJ; Kiconco M; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS;
    Lancet HIV; 2017 Aug; 4(8):e341-e348. PubMed ID: 28495562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial.
    Paton NI; Stöhr W; Arenas-Pinto A; Fisher M; Williams I; Johnson M; Orkin C; Chen F; Lee V; Winston A; Gompels M; Fox J; Scott K; Dunn DT;
    Lancet HIV; 2015 Oct; 2(10):e417-26. PubMed ID: 26423649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
    La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC;
    Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
    Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.